Since the first description of gene amplification and overexpression in human GBM in 1985 [51], EGFR structure and regulating function, along with its most-frequently mutated form (EGFRvIII), have been the focus of both pre- and clinical trials exploring different drug generations [52,53]. Here, EGFR is linked to glioblastoma.